167 related articles for article (PubMed ID: 11156211)
1. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.
Tada Y; Wada M; Kuroiwa K; Kinugawa N; Harada T; Nagayama J; Nakagawa M; Naito S; Kuwano M
Clin Cancer Res; 2000 Dec; 6(12):4618-27. PubMed ID: 11156211
[TBL] [Abstract][Full Text] [Related]
2. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression.
Gao P; Yang X; Xue YW; Zhang XF; Wang Y; Liu WJ; Wu XJ
Cancer; 2009 Jul; 115(14):3222-32. PubMed ID: 19484794
[TBL] [Abstract][Full Text] [Related]
4. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
[TBL] [Abstract][Full Text] [Related]
6. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
7. Clinical relationship between MDR1 gene and gallbladder cancer.
Wang BL; Zhai HY; Chen BY; Zhai SP; Yang HY; Chen XP; Zhao WT; Meng L
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):296-9. PubMed ID: 15138130
[TBL] [Abstract][Full Text] [Related]
8. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer.
Ribeiro-Filho LA; Franks J; Sasaki M; Shiina H; Li LC; Nojima D; Arap S; Carroll P; Enokida H; Nakagawa M; Yonezawa S; Dahiya R
Mol Carcinog; 2002 Aug; 34(4):187-98. PubMed ID: 12203370
[TBL] [Abstract][Full Text] [Related]
9. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
[TBL] [Abstract][Full Text] [Related]
11. MDR1 gene expression in primary and advanced breast cancer.
Yang X; Uziely B; Groshen S; Lukas J; Israel V; Russell C; Dunnington G; Formenti S; Muggia F; Press MF
Lab Invest; 1999 Mar; 79(3):271-80. PubMed ID: 10092063
[TBL] [Abstract][Full Text] [Related]
12. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
13. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients.
Sharma G; Mirza S; Parshad R; Srivastava A; Datta Gupta S; Pandya P; Ralhan R
Clin Biochem; 2010 Mar; 43(4-5):373-9. PubMed ID: 19879256
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance gene and P-glycoprotein expression in anaplastic carcinoma of the thyroid.
Yamashita T; Watanabe M; Onodera M; Shimaoka K; Ito K; Fujimoto Y; Itoyama S; Sugawara I
Cancer Detect Prev; 1994; 18(5):407-13. PubMed ID: 7812988
[TBL] [Abstract][Full Text] [Related]
15. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
16. Effect of promoter methylation of multidrug resistance 1 (MDR1) gene in gastric carcinogenesis.
Tahara T; Arisawa T; Shibata T; Yamashita H; Yoshioka D; Hirata I
Anticancer Res; 2009 Jan; 29(1):337-41. PubMed ID: 19331170
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing.
Baker EK; El-Osta A
Methods Mol Biol; 2010; 596():183-98. PubMed ID: 19949925
[TBL] [Abstract][Full Text] [Related]
18. Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.
Imanishi T; Abe Y; Suto R; Higaki S; Ueyama Y; Nakamura M; Tamaoki N; Fukuda H; Imai N
Tokai J Exp Clin Med; 1994 Sep; 19(1-2):39-46. PubMed ID: 7660382
[TBL] [Abstract][Full Text] [Related]
19. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
20. DBC2 gene is silenced by promoter methylation in bladder cancer.
Shi Y; Chen JY; Yang J; Li B; Chen ZH; Xiao CG
Urol Oncol; 2008; 26(5):465-9. PubMed ID: 18640857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
